{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T22:23:38Z","timestamp":1757456618958},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2012,6,3]],"date-time":"2012-06-03T00:00:00Z","timestamp":1338681600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1007\/s12032-012-0261-5","type":"journal-article","created":{"date-parts":[[2012,6,4]],"date-time":"2012-06-04T13:52:29Z","timestamp":1338817949000},"page":"3540-3546","source":"Crossref","is-referenced-by-count":11,"title":["Systemic mastocytosis: progressive evolution of an occult disease into fatal mast cell leukemia: unique findings on an unusual hematological neoplasm"],"prefix":"10.1007","volume":"29","author":[{"given":"T.","family":"G\u00fclen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Sander","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Nilsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Palmblad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Sotlar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.-P.","family":"Horny","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"H\u00e4gglund","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,6,3]]},"reference":[{"key":"261_CR1","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S0145-2126(01)00038-8","volume":"25","author":"P Valent","year":"2001","unstructured":"Valent P, Horny H-P, Escribano L, et al. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res. 2001;25:603\u201325.","journal-title":"Leuk Res"},{"key":"261_CR2","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0145-2126(02)00168-6","volume":"27","author":"P Valent","year":"2003","unstructured":"Valent P, Akin C, Sperr WR, et al. Aggressive systemic mastocytosis and related mast cell disorders: current treatment options and proposed response criteria. Leuk Res. 2003;27:635\u201341.","journal-title":"Leuk Res"},{"key":"261_CR3","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1159\/000101711","volume":"74","author":"HP Horny","year":"2007","unstructured":"Horny HP, Sotlar K, Valent P. Mastocytosis: state of the Art. Pathobiology. 2007;74:121\u201332.","journal-title":"Pathobiology"},{"issue":"6","key":"261_CR4","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/j.1365-2362.2007.01807.x","volume":"37","author":"P Valent","year":"2007","unstructured":"Valent P, Akin C, Escribano L, et al. Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest. 2007;37(6):435\u201353.","journal-title":"Eur J Clin Invest"},{"key":"261_CR5","unstructured":"Horny HP, Akin C, Metcalfe DD, Bennett JM, et al. Mastocytosis. In:Swerdlow SH, Campo E, Harris NL, et al., (eds.). World Health Organization (WHO) Classification of tumours of haematopoietic and lymphoid tissues. Lyon, France: International Agency for Research and Cancer (IARC); 2008. pp 54\u201363."},{"key":"261_CR6","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S0145-2126(01)00021-2","volume":"25","author":"HP Horny","year":"2001","unstructured":"Horny HP, Valent P. Diagnosis of mastocytosis: general histopathological aspects, morphological criteria, and immunohistochemical findings. Leuk Res. 2001;25:543\u201351.","journal-title":"Leuk Res"},{"key":"261_CR7","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1097\/00000478-199809000-00013","volume":"22","author":"HP Horny","year":"1998","unstructured":"Horny HP, Sillaber C, Menke D, et al. Diagnostic value of immunostaining for tryptase in patients with mastocytosis. Am J Surg Pathol. 1998;22:1132\u201340.","journal-title":"Am J Surg Pathol"},{"issue":"8","key":"261_CR8","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1182\/blood.V91.8.2731.2731_2731_2736","volume":"91","author":"L Escribano","year":"1998","unstructured":"Escribano L, Orfao A, D\u00edaz-Agustin B, Villarrubia J, et al. Indolent systemic mast cell disease in adults: immunophenotypic characterization of bone marrow mast cells and its diagnostic implications. Blood. 1998;91(8):2731\u20136.","journal-title":"Blood"},{"key":"261_CR9","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S0145-2126(01)00041-8","volume":"25","author":"WR Sperr","year":"2001","unstructured":"Sperr WR, Escribano L, Jordan JH, et al. Morphologic properties of neoplastic mast cells: delineation of stages of maturation and implication for cytological grading of mastocytosis. Leuk Res. 2001;25:529\u201336.","journal-title":"Leuk Res"},{"key":"261_CR10","doi-asserted-by":"crossref","unstructured":"Morgado JM, S\u00e1nchez-Mu\u00f1oz L, Teod\u00f3sio CG, Jara-Acevedo M, et al. Immunophenotyping in systemic mastocytosis diagnosis: \u2018CD25 positive\u2019 alone is more informative than the \u2018CD25 and\/or CD2\u2019 WHO criterion. Mod Pathol. 2012 Jan 6. doi: 10.1038\/modpathol.2011.192 . [Epub ahead of print].","DOI":"10.1038\/modpathol.2011.192"},{"key":"261_CR11","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/S0002-9440(10)63870-9","volume":"162","author":"K Sotlar","year":"2003","unstructured":"Sotlar K, Escribano L, Landt O, et al. One-step detection of c-kit point mutations using peptide nucleic acid-mediated polymerase chain reaction clamping and hybridization probes. Am J Pathol. 2003;162:737\u201346.","journal-title":"Am J Pathol"},{"key":"261_CR12","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1136\/mp.53.4.188","volume":"53","author":"K Sotlar","year":"2000","unstructured":"Sotlar K, Marafioti T, Griesser H, et al. Detection of c-kit mutation Asp-816-Val in microdissected bone marrow infiltrates in a case of systemic mastocytosis associated with chronic myelomonocytic leukemia. Mol Pathol. 2000;53:188\u201393.","journal-title":"Mol Pathol"},{"key":"261_CR13","doi-asserted-by":"crossref","first-page":"10560","DOI":"10.1073\/pnas.92.23.10560","volume":"92","author":"H Nagata","year":"1995","unstructured":"Nagata H, Worobec AS, Oh CK, et al. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci USA. 1995;92:10560\u20134.","journal-title":"Proc Natl Acad Sci USA"},{"key":"261_CR14","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1159\/000048179","volume":"127","author":"F Feger","year":"2002","unstructured":"Feger F, Ribadeau Dumas A, Leriche L, et al. Kit and c-kit mutations in mastocytosis: a short overview with special reference to novel molecular and diagnostic concepts. Int Arch Allergy Immunol. 2002;127:110\u20134.","journal-title":"Int Arch Allergy Immunol"},{"key":"261_CR15","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S0145-2126(01)00028-5","volume":"25","author":"BJ Longley","year":"2001","unstructured":"Longley BJ, Reguera MJ, Ma Y. Classes of c-KIT activating mutations: proposed mechanisms of action and implications for disease classification and therapy. Leuk Res. 2001;25:571\u20136.","journal-title":"Leuk Res"},{"key":"261_CR16","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1136\/jcp.2003.014860","volume":"57","author":"HP Horny","year":"2004","unstructured":"Horny HP, Sotlar K, Sperr WR, et al. Systemic mastocytosis with associated clonal haematological non- mast cell lineage diseases: a histopathological challenge. J Clin Pathol. 2004;57:604\u20138.","journal-title":"J Clin Pathol"},{"issue":"1","key":"261_CR17","doi-asserted-by":"crossref","first-page":"58","DOI":"10.2353\/jmoldx.2008.070061","volume":"10","author":"K Sotlar","year":"2008","unstructured":"Sotlar K, Bache A, Stellmacher F, et al. Systemic mastocytosis associated with chronic idiopathic myelofibrosis: a distinct subtype of systemic mastocytosis associated with a [corrected] clonal hematological non-mast [corrected] cell lineage disorder carrying the activating point mutations KITD816\u00a0V and JAK2V617F. J Mol Diagn. 2008;10(1):58\u201366.","journal-title":"J Mol Diagn"},{"key":"261_CR18","doi-asserted-by":"crossref","first-page":"473","DOI":"10.3109\/10428190009058500","volume":"37","author":"WR Sperr","year":"2000","unstructured":"Sperr WR, Horny H-P, Lechner K, et al. Clinical and biologic diversity of leukemias occurring in patients with mastocytosis. Leuk Lymphoma. 2000;37:473\u201386.","journal-title":"Leuk Lymphoma"},{"issue":"3\u20134","key":"261_CR19","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s002770050382","volume":"76","author":"W Hagen","year":"1998","unstructured":"Hagen W, Schwarzmeier J, Walchshofer S, et al. A case of bone marrow mastocytosis associated with multiple myeloma. Ann Hematol. 1998;76(3\u20134):167\u201374.","journal-title":"Ann Hematol"},{"issue":"8","key":"261_CR20","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1136\/jcp.2008.058073","volume":"61","author":"A Tzankov","year":"2008","unstructured":"Tzankov A, Sotlar K, Muhlematter D, et al. Systemic mastocytosis with associated myeloproliferative disease and precursor B lymphoblastic leukaemia with t(13;13)(q12;q22) involving FLT3. J Clin Pathol. 2008;61(8):958\u201361.","journal-title":"J Clin Pathol"},{"issue":"3","key":"261_CR21","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.jaci.2007.05.024","volume":"120","author":"I Maric","year":"2007","unstructured":"Maric I, Robyn J, Metcalfe DD, et al. KIT D816\u00a0V-associated systemic mastocytosis with eosinophilia and FIP1L1\/PDGFRA-associated chronic eosinophilic leukemia are distinct entities. J Allergy Clin Immunol. 2007;120(3):680\u20137.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"261_CR22","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jaci.2007.03.015","volume":"120","author":"A B\u00f6hm","year":"2007","unstructured":"B\u00f6hm A, F\u00f6dinger M, Wimazal F, et al. Eosinophilia in systemic mastocytosis: clinical and molecular correlates and prognostic significance. J Allergy Clin Immunol. 2007;120(1):192\u20139.","journal-title":"J Allergy Clin Immunol"},{"key":"261_CR23","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1182\/blood-2003-06-1824","volume":"103","author":"J Gotlib","year":"2004","unstructured":"Gotlib J, Cools J, Malone JM, et al. The FIP1L1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management. Blood. 2004;103:2879\u201391.","journal-title":"Blood"},{"key":"261_CR24","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1182\/blood-2004-03-0787","volume":"104","author":"A Pardanani","year":"2004","unstructured":"Pardanani A, Brockman SR, Paternoster SF, et al. FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia. Blood. 2004;104:3038\u201345.","journal-title":"Blood"},{"key":"261_CR25","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1182\/blood-2003-05-1627","volume":"102","author":"A Pardanani","year":"2003","unstructured":"Pardanani A. H.C. Flynn, S.F. Paternoster and B.M. Shearer et al., CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. Blood. 2003;102:3093\u20136.","journal-title":"Blood"},{"key":"261_CR26","unstructured":"Bain B, Pierre R, Imbert M, et al. Chronic eosinophilic leukemia and hypereosinophilic syndrome. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, editors, World Health Organization (WHO) classification of tumours. Pathology & genetics. Tumours of haematopoietic and lymphoid tissues vol. 1; 2001. pp. 29\u201331."},{"key":"261_CR27","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa025217","volume":"348","author":"J Cools","year":"2003","unstructured":"Cools J, DeAngelo DJ, Gotlib J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med. 2003;348:1201\u201314.","journal-title":"N Engl J Med"},{"key":"261_CR28","doi-asserted-by":"crossref","first-page":"4660","DOI":"10.1182\/blood-2003-01-0006","volume":"101","author":"AD Klion","year":"2003","unstructured":"Klion AD, Noel P, Akin C, et al. Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness. Blood. 2003;101:4660\u20136.","journal-title":"Blood"},{"key":"261_CR29","doi-asserted-by":"crossref","first-page":"4714","DOI":"10.1182\/blood-2003-01-0081","volume":"101","author":"J Cortes","year":"2003","unstructured":"Cortes J, Ault P, Koller C, et al. Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome. Blood. 2003;101:4714\u20136.","journal-title":"Blood"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-012-0261-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12032-012-0261-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-012-0261-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,8]],"date-time":"2020-07-08T09:51:08Z","timestamp":1594201868000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12032-012-0261-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6,3]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["261"],"URL":"https:\/\/doi.org\/10.1007\/s12032-012-0261-5","relation":{},"ISSN":["1357-0560","1559-131X"],"issn-type":[{"value":"1357-0560","type":"print"},{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,6,3]]}}}